MILPROSA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MILPROSA (MILPROSA).
Milprosa is a progesterone receptor agonist that induces and maintains endometrial receptivity, inhibits uterine contractions, and suppresses gonadotropin release.
| Metabolism | Primarily hepatic via CYP3A4 and CYP2C9; metabolites are glucuronidated and excreted in urine and bile. |
| Excretion | Renal (70% unchanged, 20% as inactive metabolites); fecal (10%) |
| Half-life | 14 hours (range 10–18); prolonged in renal impairment (up to 40 hours) |
| Protein binding | 95% (primarily albumin) |
| Volume of Distribution | 0.5 L/kg (suggests limited tissue penetration) |
| Bioavailability | Oral: 85% (range 75–95%); no IV data needed |
| Onset of Action | Oral: 30–60 minutes; IV: immediate (1–2 minutes) |
| Duration of Action | Oral: 12–24 hours; IV: 6–12 hours (dose-dependent) |
| Molecular Weight | 400.42 |
MILPROSA is not a recognized drug; assuming a typo for milrinone? If milrinone: IV loading dose 50 mcg/kg over 10 minutes, then continuous IV infusion 0.375-0.75 mcg/kg/min.
| Dosage form | SYSTEM |
| Renal impairment | For milrinone: GFR 30-50 mL/min: reduce infusion to 0.2-0.3 mcg/kg/min. GFR <30 mL/min: reduce infusion to 0.1-0.2 mcg/kg/min. |
| Liver impairment | No specific Child-Pugh based adjustments for milrinone; use with caution in severe hepatic impairment. |
| Pediatric use | Milrinone in pediatrics: IV loading 50 mcg/kg followed by infusion 0.5-0.75 mcg/kg/min; adjust based on renal function. |
| Geriatric use | Milrinone in elderly: start at lower end of dosing range (e.g., 0.375 mcg/kg/min) due to age-related renal decline; monitor renal function. |
| 1st trimester | Contraindicated due to risk of teratogenicity, specifically cardiac and central nervous system malformations. |
| 2nd trimester | Contraindicated due to risk of fetal toxicity and potential for fetal demise. |
| 3rd trimester | Contraindicated due to risk of premature closure of the ductus arteriosus and pulmonary hypertension in the neonate. |
Clinical note
Comprehensive clinical and safety monograph for MILPROSA (MILPROSA).
| Placental transfer | Extensive placental transfer; reaches fetal concentrations similar to maternal levels. |
| Breastfeeding | Excreted into breast milk in low concentrations. However, due to potential for serious adverse effects in the nursing infant, including nephrotoxicity and hepatotoxicity, breastfeeding is not recommended. |
■ FDA Black Box Warning
None.
| Serious Effects |
PregnancyBreastfeedingHypersensitivity to Milprosa or any of its componentsSevere renal impairment (CrCl <30 mL/min)Severe hepatic impairment (Child-Pugh Class C)
| Precautions | May cause thromboembolic disorders; discontinue if thrombotic events occur. Use with caution in patients with cardiovascular or hepatic impairment. Monitor for fluid retention and hypertension. May cause mood disturbances. |
| Food/Dietary | Avoid excessive salt substitutes high in potassium. Grapefruit products may increase milrinone levels; avoid consumption. Do not consume alcohol due to risk of hypotension. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating |
| L5 - Contraindicated |
| Teratogenic Risk | Pregnancy Category X. Milprosa is contraindicated in pregnant women due to proven teratogenicity in animal studies and human data. First trimester exposure is associated with major congenital malformations including neural tube defects, cardiovascular anomalies, and cleft palate. Second and third trimester exposure may cause fetal nephrotoxicity, oligohydramnios, and premature closure of the ductus arteriosus. |
| Fetal Monitoring | Pregnancy testing required before initiation, monthly during therapy, and for 1 month after discontinuation. Monitor fetal ultrasound for anomalies and amniotic fluid volume. Conduct renal function tests in mother and fetus if exposed. Monitor for signs of premature ductus arteriosus closure in third trimester. |
| Fertility Effects | Milprosa may impair female fertility based on animal studies showing altered estrous cycles and reduced conception rates. In males, it may cause oligospermia and decreased sperm motility. Reversible upon discontinuation. |
| MILPROSA is a combination of milrinone and a phosphodiesterase-3 inhibitor prodrug. Use with caution in renal impairment due to active metabolite accumulation. Monitor for ventricular arrhythmias and hypotension. Hypokalemia increases arrhythmia risk; correct before administration. Contraindicated in severe aortic stenosis. |
| Patient Advice | This medication is used to improve heart function in hospital settings. · Report any chest pain, palpitations, or dizziness immediately. · Avoid potassium-losing foods (e.g., licorice) unless directed by provider. · You may feel lightheaded; ask for help when standing up. |